drugset / Trial / NCT03183024

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

NCT03183024

Phase 4 Completed 12 enrolled Jonathan A. Bernstein, MD
Non-randomizedParallel-groupSingle-blindTreatment

Summary

Study to determine the efficacy of benralizumab when compared to placebo in patients with chronic hives that do not respond to antihistamine treatment

Timeline

Start
2017-09-12
Primary completion
2018-11-06
Completion
2018-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody Subcutaneous